Clinical Trials Logo

mCRC clinical trials

View clinical trials related to mCRC.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05690035 Not yet recruiting - Clinical trials for Metastatic Colorectal Cancer

Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer

Start date: February 2023
Phase: Phase 2
Study type: Interventional

This is an open-label phase II study, with the aim of investigating the efficacy and safety of Tislelizumab + Fruquintinib combination therapy in ARID1A-mutated pMMR/MSS metastatic colorectal cancer who have been treated with standard chemotherapy that includes fluoropyrimidine, oxaliplatin, and irinotecan. Patients with hypermutated CRC that carries POLE/POLD1 mutations cannot be included.